Allergan (AGN) agrees to acquire MAP Pharmaceuticals (MAPP) for $958M ($25/share) in cash, a 60%...

|About: Allergan plc (AGN)|By:, SA News Editor

Allergan (AGN) agrees to acquire MAP Pharmaceuticals (MAPP) for $958M ($25/share) in cash, a 60% premium over MAP's Tuesday close. MAP's experimental migraine drug Levadex is set to receive a regulatory decision by April 15; Botox maker Allergan (which already had rights to help market Levadex) is showing confidence in an OK by taking total control.